Robert Brown

Dr. Robert Brown, D.Phil, MD, is a distinguished Professor at the Horae Gene Therapy Center within UMass Chan Medical School. With a prolific research career spanning over three decades, Dr. Brown has established himself as a leading expert in amyotrophic lateral sclerosis (ALS) research and gene therapy approaches for neurodegenerative diseases. His work has significantly advanced our understanding of the molecular mechanisms underlying ALS and related disorders.

Dr. Brown's research primarily focuses on the genetic and molecular basis of ALS, with particular emphasis on superoxide dismutase (SOD1) mutations, TDP-43 pathology, and C9ORF72 hexanucleotide expansions. His laboratory has pioneered gene therapy approaches using adeno-associated viral (AAV) vectors to target disease mechanisms in ALS models. Dr. Brown's work spans from basic molecular investigations to translational studies and clinical trials, demonstrating his commitment to bridging the gap between laboratory discoveries and patient care.

His extensive publication record, with over 200 peer-reviewed articles in top-tier journals, reflects his leadership in the field. Dr. Brown has secured continuous funding from major organizations including the NIH and ALS Association to support his research program. His work on SOD1 silencing, protein misfolding, and axonal degeneration pathways has provided critical insights into disease mechanisms and identified promising therapeutic targets.

Dr. Brown has trained numerous graduate students and postdoctoral fellows who have gone on to establish successful careers in neuroscience and neurology. He serves on editorial boards for major neuroscience journals and regularly presents his work at international conferences. His leadership extends to collaborative efforts with other institutions and participation in multi-center clinical trials for ALS therapies.